Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

An investigational once-weekly amylin receptor agonist conferred substantial weight loss across six different dosing regimens for adults with overweight or obesity, researchers reported in a phase 2 ...

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...

We made several strategic additions during market weakness including Fast Retailing, Chipotle, Gartner and Adyen. Read more here.

Eli Lilly has raised the stakes in the obesity market with midstage data for an amylin-targeting drug, eloralintide, that ...

The analysts see “meaningful skew to the downside” as around one-third of Roche’s 2030 revenue is at risk from competitors targeting major franchises such as Vabysmo, Perjeta, Hemlibra, Alecensa, and ...

Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for ...